My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 531739 | NSE: | Pharmaceuticals & Drugs | Small Cap
1. Is Gennex Laboratories Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gennex Laboratories Ltd is a below average quality company.
2. Is Gennex Laboratories Ltd undervalued or overvalued?
The key valuation ratios of Gennex Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Gennex Laboratories Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gennex Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 2.2% | 1.2% | 3.3% | 9% | 9.9% | 3.9% | 7.6% | 5.5% | 10.4% | 8.4% | - | ||
| Value Creation Index ⓘ | -0.8 | -0.9 | -0.8 | -0.4 | -0.3 | -0.7 | -0.5 | -0.6 | -0.3 | -0.4 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 29.9 | 35 | 31.9 | 38.6 | 41.9 | 43.8 | 55.8 | 55.6 | 59.7 | 61.2 | 67 | ||
| YoY Gr. Rt. % | - | 17% | -8.8% | 20.9% | 8.7% | 4.5% | 27.5% | -0.3% | 7.3% | 2.6% | - | ||
| Adj EPS ⓘ | 0 | 0 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 | 0.2 | ||
| YoY Gr. Rt. % | - | -66.7% | 400% | 260% | 16.7% | -71.4% | 183.3% | -29.4% | 158.3% | -9.7% | - | ||
| BVPS (₹) ⓘ | 1.9 | 1.9 | 1.9 | 2.1 | 2.3 | 2.4 | 2.6 | 2.7 | 3 | 3.3 | 2.9 | ||
| Adj Net Profit ⓘ | 0.4 | 0.1 | 0.6 | 2.4 | 2.7 | 0.9 | 2.2 | 1.6 | 4.1 | 3.7 | 4 | ||
| Cash Flow from Ops. ⓘ | -1.7 | 0.5 | 0.2 | 3.4 | -0.1 | 3.2 | 1.9 | -1.7 | -1.4 | 6.6 | - | ||
| Debt/CF from Ops. ⓘ | -1.4 | 6.5 | 18.6 | 0.7 | -36.2 | 0.8 | 2.4 | -3 | -5.1 | 1.5 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 8.3% | 7.9% | 3.1% | 2.6% | ||||||||
| Adj EPS ⓘ | 28.2% | 5.9% | 18.1% | -9.7% | ||||||||
| BVPS ⓘ | 6.4 | 7.3 | 9.1 | 10.3 | ||||||||
| Share Price | 25.2% | 16.3% | 20.7% | 2.3% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 1.6 | 0.4 | 2.5 | 8.7 | 9.2 | 2.7 | 6.7 | 4.7 | 10.7 | 8.7 | 7.1 | |
| Op. Profit Mgn % ⓘ | 5.1 | 4.7 | 6.3 | 10.9 | 10.9 | 5.2 | 7.2 | 5.8 | 11 | 8.8 | 7.9 | |
| Net Profit Mgn % ⓘ | 1.3 | 0.3 | 2 | 6.1 | 6.5 | 2 | 4 | 2.9 | 6.8 | 6 | 5.9 | |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | - | |
| Working Cap Days ⓘ | 129 | 147 | 181 | 160 | 185 | 203 | 161 | 184 | 204 | 213 | 0 | |
| Cash Conv. Cycle ⓘ | -3 | -13 | -12 | 6 | 10 | 2 | 15 | 33 | 25 | 41 | 0 | |
Net Profit is growing at healthy rate in last 3 years 18.10%
Sales growth is good in last 4 quarters at 19.53%
Return on Equity has declined versus last 3 years average to 7.10%
Sales growth has been subdued in last 3 years 3.13%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.2 | 0.2 |
| TTM Sales (₹ Cr.) | 67.1 | 61.2 |
| BVPS (₹.) ⓘ | 2.9 | 3.3 |
| Reserves (₹ Cr.) ⓘ | 34 | 42 |
| P/BV ⓘ | 2.36 | 2.06 |
| PE ⓘ | 31.07 | 29.96 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 4.81 / 9.10 |
| All Time Low / High (₹) | 0.22 / 14.16 |
| Market Cap (₹ Cr.) | 123 |
| Equity (₹ Cr.) | 17.9 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 38.1 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 8.07 | 8.07 | 8.07 | 8.84 | 3.46 | 3.46 |
Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.
The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.
The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The company’s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.
Products of the company:
Certification:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
